NNV 014
Alternative Names: NN-ATACs; NNV 014Latest Information Update: 24 Sep 2019
At a glance
- Originator Heidelberg Pharma; Nordic Nanovector
- Developer Heidelberg Pharma Research; Nordic Nanovector
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Leukaemia